Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
暂无分享,去创建一个
E Novellino | A Lavecchia | E. Novellino | G. Greco | A. Lavecchia | A. Mai | M. Artico | G. Sbardella | R. Loddo | P. la Colla | R. Ragno | S. Massa | P. Colla | C. Musiu | M Artico | M. La Colla | G Greco | A Mai | G Sbardella | R Ragno | S Massa | C Musiu | M La Colla | C Murgioni | P La Colla | R Loddo | C. Murgioni | M. L. Colla | Aantonio Lavecchia
[1] Erik De Clercq,et al. Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections. , 1995 .
[2] A. Mai,et al. Chiral resolution and molecular modeling investigation of rac-2-cyclopentylthio-6-[1-(2,6-difluorophenyl)ethyl]-3,4-dihydro-5-methylpyrimidin-4(3H)-one (MC-1047), a potent anti-HIV-1 reverse transcriptase agent of the DABO class. , 2001, Chirality.
[3] M. Summers,et al. Structural biology of HIV. , 1999, Journal of molecular biology.
[4] D. Richman. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents , 1993, Antimicrobial Agents and Chemotherapy.
[5] Richard T. Walker,et al. Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. , 1996, Journal of medicinal chemistry.
[6] A. Mai,et al. Synthesis and Antiviral Activity of New 3,4-Dihydro-2-Alkoxy-6-Benzyl-4-Oxopyrimidines (DABOs), Specific Inhibitors of Human Immunodeficiency Virus Type 1 , 1995 .
[7] M A Fischl,et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. , 1987, The New England journal of medicine.
[8] A. D. Clark,et al. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. , 1996, Journal of molecular biology.
[9] D W Barry,et al. 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[10] T. Terasaki,et al. Restricted transport of 3'-azido-3'-deoxythymidine and dideoxynucleosides through the blood-brain barrier. , 1988, The Journal of infectious diseases.
[11] W. L. Jorgensen,et al. Binding affinities for sulfonamide inhibitors with human thrombin using Monte Carlo simulations with a linear response method. , 1997, Journal of medicinal chemistry.
[12] R T Walker,et al. Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative. , 1989, Biochemical and biophysical research communications.
[13] A. D. Clark,et al. Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor α-APA R 95845 at 2.8 å resolution , 1995 .
[14] Peter A. Kollman,et al. AMBER, a package of computer programs for applying molecular mechanics, normal mode analysis, molecular dynamics and free energy calculations to simulate the structural and energetic properties of molecules , 1995 .
[15] G J Williams,et al. The Protein Data Bank: a computer-based archival file for macromolecular structures. , 1977, Journal of molecular biology.
[16] E. Clercq. Targets and strategies for the antiviral chemotherapy of AIDS , 1990 .
[17] J Desmyter,et al. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. , 1988, Journal of virological methods.
[18] T. Steitz,et al. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[19] D. Stuart,et al. The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design. , 1995, Structure.
[20] E. Clercq,et al. Antiviral therapy for human immunodeficiency virus infections. , 1995 .
[21] L. Resnick,et al. Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[22] M. Zerner,et al. A Broyden—Fletcher—Goldfarb—Shanno optimization procedure for molecular geometries , 1985 .
[23] Erik De Clercq,et al. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection , 1998 .
[24] Eamonn F. Healy,et al. Development and use of quantum mechanical molecular models. 76. AM1: a new general purpose quantum mechanical molecular model , 1985 .
[25] A. Mai,et al. Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series. , 1997, Journal of medicinal chemistry.
[26] A. Mai,et al. Characterization of the anti-HIV-1 activity of 3,4-dihydro-2-alkoxy-6-benzyl-4-oxopyrimidines (DABOs), new non-nucleoside reverse transcriptase inhibitors. , 1994, The new microbiologica.
[27] Oberg,et al. Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues , 1999, Journal of medicinal chemistry.
[28] K. Weinhold,et al. 3'-Azido-3'-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase , 1987, Antimicrobial Agents and Chemotherapy.
[29] J. Adams,et al. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. , 1990, Science.
[30] H. Berendsen,et al. Molecular dynamics with coupling to an external bath , 1984 .
[31] P. Kollman,et al. A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules , 1995 .
[32] D. Stuart,et al. High resolution structures of HIV-1 RT from four RT-inhibitor complexes. , 1996 .
[33] A. Mai,et al. 3,4-Dihydro-2-Alkoxy-6-Benzyl-4-Oxopyrimidines (DABOs): A New Class of Specific Inhibitors of Human Immunodeficiency Virus Type 1 , 1993 .
[34] Erik De Clercq,et al. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives , 1990, Nature.
[35] D I Stuart,et al. Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[36] A. Skalka,et al. The retroviral enzymes. , 1994, Annual review of biochemistry.